Federal Regulators Publish Generic Development Roadmaps for Epinephrine, ADHD Stimulants and Levothyroxine as Comment Window Opens
The FDA published 48 draft generic development guidances covering epinephrine, ADHD stimulants, and levothyroxine, with public comments due October 23.
Medical Daily ·